TruScreen Group with Proactive at ASX Small and Mid Cap Conference

TruScreen Group Ltd (ASX:TRU) CEO Martin Dillon joins Proactive's Jonathan Jackson live from the ASX Small and Mid Cap Conference. TruScreen has developed a disruptive cervical cancer screening device. The TruScreen Cervical Cancer Screening Device comprises a medical device and an AI-enabled process designed to detect the presence of pre-cancerous and cancerous tissue of the cervix in real time. The company recently announced that planning is in progress for clinical evaluation trials in Indonesia and Kenya which are a prelude to wider market access in future years.